Prophylactic or therapeutic agent for porphyria

MYPI2025005711A0Undetermined Publication Date: 2021-12-10TANABE PHARMA CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025005711
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-08-07
Filing Date
2021-06-10
Publication Date
2021-12-10
Patent Text Reader

Abstract

A medicament for treatment or prevention of porphyria, comprising 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or a pharmaceutically acceptable salt or cocrystal thereof as an active ingredient, wherein the dose of the 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid or the pharmaceutically acceptable salt or cocrystal thereof is 50 to 500 mg / day.
Need to check novelty before this filing date? Find Prior Art